IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Shenzhen Dobot 02432.HK	Advanced hardware and software	18.8-20.8	200	4,202	2024/12/18	Data is not available	2024/12/23
Minieye Tec 02431.HK	Application Software	17-20.2	200	4,081	2024/12/20	2024/12/24	2024/12/27
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	2024/12/27	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	2024/12/27	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	2024/12/27	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Shenzhen Dobot
02432.HK

Advanced hardware and software

18.8-20.8

200

4,202

2024/12/18

Data is not available

2024/12/23

Minieye Tec
02431.HK

Application Software

17-20.2

200

4,081

2024/12/20

2024/12/24

2024/12/27

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

2024/12/27

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

2024/12/27

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

2024/12/27

2024/12/30

Summary

Founded in 2014, we are a bio-pharmaceutical company focusing on the research and development of oncology therapies for cancer patients, especially those who require long-term care. Our core business model is to develop and commercialize oncology products and drug candidates through a combination of co-development, in-licensing and in-house discovery. We plan to further enhance our in-house discovery capabilities and continue to conduct clinical trials for more indications benefiting chronic cancer patients by utilizing the co-development and in-licensing models after the Listing. As of the Latest Practicable Date, we have built a pipeline consisting of one Core Product and 11 drug candidates, among which, the Core Product envafolimab (brand name: ENWEIDA, 恩維達), as our backbone, was approved in November 2021 and commercialized in December 2021, and seven other drug candidates are in clinical stage (including those drug candidates for which we have initiated clinical trials or have received IND approvals and are preparing for initiation of clinical trials). Our Core Product envafolimab is a subcutaneously injectable PD-L1 antibody that has been approved in China for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) advanced solid tumors. As of the Latest Practicable Date, our Core Product was approved for this one indication only. According to Frost and Sullivan, there were four commercialized peers and five clinical-stage peers competing with the Core Product in respect of the treatment of MSI-H/dMMR tumor in China as of the Latest Practicable Date. We face fierce competition from existing products and potential drug candidates in the entire oncology market, including monoclonal and bispecific antibodies that target PD-1/L1, and the market opportunities in respect of the Core Product may be small as it targets late line treatment for most of its targeted indications. For instance, the incidence of MSI-H/dMMR advanced solid tumors in China reached approximately 146,100 in 2021 and is expected to reach approximately 186,000 in 2030, and only approximately 50% of the incidence will receive more than one treatment. WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR CORE PRODUCT ENVAFOLIMAB FOR INDICATIONS OTHER THAN THE APPROVED INDICATION IN PREVIOUSLY TREATED MSI-H/DMMR ADVANCED SOLID TUMORS. Our Core Product and Other Drug Candidates Envafolimab – Our Core Product Our envafolimab (brand name: ENWEIDA, 恩維達) is a subcutaneously-injectable PD-L1 inhibitor for the treatment of tumor-agnostic indications, and it has been approved in China for the treatment of previously treated MSI-H/dMMR advanced solid tumors. Envafolimab is a fusion protein of single domain PD-L1 antibody and we are solely responsible for, and are conducting its clinical development in the oncology field. Envafolimab was originally discovered and developed by Alphamab Group and was in pre-clinical stage when the Co-Development Agreements were first entered into between the Company and Alphamab Group in February 2016. Since then, we have been independently conducting or completed all clinical trials of envafolimab for oncology indications globally (except for sarcoma (SC) which we out-licensed to TRACON), and achieved a number of major R&D milestones on our own and at our own cost, which amounted to approximately RMB614.9 million as of May 31, 2022. In November 2016 and May 2017, we obtained the IND approvals from FDA and PMDA to commence the Phase I clinical trials of envafolimab in the U.S. and Japan, respectively. In December 2016, we received an umbrella IND approval from NMPA for Phase I, II and III clinical trials of envafolimab. In June 2018, we submitted consultation to Center for Drug Evaluation (CDE) in respect of the exploratory Phase II clinical trial of envafolimab for G/GEJ advanced cancer, and we completed this trial in February 2021. In July 2020, we completed the pivotal Phase II clinical trial of envafolimab for the treatment of previously treated MSI-H/dMMR advanced solid tumors, and we submitted the BLA for envafolimab for this indication to NMPA in November 2020, which was accepted by NMPA in December 2020. On November 24, 2021, we received BLA approval for this indication from NMPA. In addition, envafolimab has undergone an exploratory Phase II clinical trial in China in gastric or gastroesophageal junction (G/GEJ) advanced cancer, and is currently being evaluated in two ongoing pivotal clinical trials including a Phase III clinical trial in patients with advanced biliary tract carcinoma (BTC) in China, and a Phase II clinical trial in selected types of advanced sarcoma (SC) in the U.S. sponsored by our partner TRACON. On January 16, 2020, the U.S. Food and Drug Administration (FDA) granted envafolimab with orphan drug designation for the treatment of advanced BTC. On June 28, 2021, the FDA granted envafolimab with orphan drug designation for the treatment of soft tissue sarcoma, of which the clinical trial is sponsored by our partner TRACON. For more details, please refer to the paragraphs headed “Business – Our Core Product and Other Drug Candidates – 1. Our Core Product – a. Envafolimab” in this document. Our Other Drug Candidates ‧ 3D189: Our 3D189 is a peptide cancer vaccine that targets the Wilms Tumor 1 (WT1) protein, which is present and over-expressed in an array of hematological malignancies and solid tumors. ‧ 3D229: Our 3D229 is a high-affinity, soluble Fc-fusion protein designed to bind Growth Arrest Specific 6 (GAS6), intercept the binding of GAS6 to its receptor AXL and block the activation of the GAS6-AXL signaling pathway. ‧ 3D011: Our 3D011 is an in-house discovered tyrosine kinase inhibitor (TKI) prodrug that will be developed as monotherapy and in combination with other agents for the treatment of solid tumors. ‧ 3D185: Our 3D185 is a fibroblast growth factor receptors (FGFR) 1-3 and colony stimulating factor 1 receptor (CSF1R) inhibitor. ‧ 3D1001: Our 3D1001 is a third-generation cyclooxygenase-2 (COX-2) inhibitor with rapid onset of action and prolonged pain relief to patients with post-surgical dental pain in clinical study attributable to a favorable PK profile. ‧ 3D1002: Our 3D1002 is an E-type prostanoid receptor 4 (EP4) receptor antagonist. ‧ 3D197: Our 3D197 is a next-generation fully human anti-CD47 IgG4, one of the human immunoglobulin G, the most common antibody type found in blood circulation that plays an important role in antibody-based immunity against invading pathogens, monoclonal antibody. ‧ Our Pre-Clinical Stage Drug Candidates: In addition to our clinical-stage drug candidates, we are also evaluating a number of pre-clinical stage drug candidates in our pipeline, including, (a) 3D057, our bispecific antibody drug which targets CD3 receptor of T-cells and PD-L1 of tumor cells, (b) 3D059, our next-generation immunotherapeutic which targets the WT1 protein in hematological malignancies and solid tumors, (c) 3D060, our in-house developed monoclonal antibody which targets Semaphorin 4D (Sema4D) of tumor cells, and (d) 3D062, our in-house developed small molecule for patients with KRAS mutation. Source: 3D Medicines-B (01244) Prospectus (IPO Date : 2022/11/29)
Listing Market	MAIN
Industry	Biotechnology - Supplies & Services
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Gong Zhaolong (29.85%) [02096] Simcere Pharmaceutical Group Limited (8.93%) Kastle Limited (7.41%) Zhu Pai (5.33%) Shenzhen Efung Investment Management Enterprise (L.P.) (5.31%)
Directors	Gong Zhaolong (Founder and Chairman and Chief Executive Officer and Executive Director) Chen Yawen (Non-Executive Director) Zhou Feng (Non-Executive Director) Zhu Pai (Non-Executive Director) Li Jin (Independent Non-Executive Director) Lin Tat Pang (Independent Non-Executive Director) Liu Xinguang (Independent Non-Executive Director)
Company Secretary	Li Ching Yi Xia Fang
Principal Bankers	China CITIC Bank Corporation Limited
Solicitors	Conyers Dill & Pearman O Melveny & Myers LLP Zhong Lun Law Firm
Auditors	Modern Assure CPA
Registered Office	19th Floor, Golden Centre, 188 Des Voeux Road, Central, Hong Kong
Share Registrars	Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No	(852) 2980-1333
Internet Address	https://www.3d-medicines.com/
Email Address	ir@3d-medicines.com
Tel No	(86 010) 6788-8635
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates